Most obesity drugs, including GLP‑1 receptor agonists, work by reducing appetite. MT-1101 works on the other side of energy balance, safely increasing the energy the body spends by accelerating the natural fat-burning process in mitochondria.

This approach is designed to complement today's treatments: to add to the weight loss achieved with GLP‑1s, to help maintain weight after GLP‑1 treatment stops, and to preserve muscle while fat is lost. Mitotech is preparing to move MT-1101 into Phase 1b in high-BMI population.

Our work builds on two decades of research in mitochondrial biology. Our team brings experience across drug discovery, clinical development, regulatory filings, partnering and exit. We work with the pharmaceutical ecosystem to take MT-1101 through late-stage development and to patients.